INC Research is not fazed by the four phases a new drug has to go through to get from idea stage to commericial adoption. The contract research organization (CRO) specializes in conducting Phase I through Phase IV clinical trials on drugs addressing a range of disorders. Its services include scientific and medical consulting, study monitoring, project management, data management, and regulatory support services. It also has divisions devoted to pediatrics and women's health trials and operates in 40 countries around the globe. The company is owned by a consortium of private equity investors.
INC Research has locations in North America and Western, Central, and Eastern Europe and Asia (India).
Fueled by an increased capital base courtesy of new owners, in 2011 the company acquired fellow CRO Kendle International for some $232 million in cash. The purchase grew its operations significantly, bringing INC Research into the top ranks of global CRO players, and allowed the combined company to better serve customers of all sizes by providing a wider offering of development outsourcing and partnering services. The agreement came as Kendle was experiencing financial woes due to a downturn in the CRO industry, prompted by economic conditions and competitive factors in the pharmaceuticals market. After the deal closed, Kendle ceased operating as a stand-alone entity.
INC Research also added a consulting division to help drugmakers navigate through the process of conducting clinical trials when it acquired North Carolina-based AVOS Life Sciences in early 2011. INC Research integrated the purchase into a new segment called AVOS Consulting; the division helps drug developers design their business plans and assists with capital allocation and pricing.
Growing its global footprint, the company acquired Trident Clinical Research in 2011. The acquisition expanded its clinical trials outsourcing footprint and expertise in Australia, New Zealand, and India. Trident's office in Mumbai increased the reach of INC Research's already sizeable clinical and data operations located in Gurgaon, India.
In 2010 INC Research's primary investors, a consortium led by Crosspoint Venture Partners and Adams Street Partners, sold control of the company to two other private equity firms, Avista Capital Partners and Teachers' Private Capital (the asset investment unit of Ontario Teachers' Pension Plan).
INC Research was formed in 1998 as a result of the merger between the Neuroclinical Trials Center and the Integrated Neuroscience Consortium. – less